Decrease of atazanavir and lopinavir plasma concentrations in a boosted double human immunodeficiency virus protease inhibitor salvage regimen

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 6, 2008, Pages 2273-2275

  Von Hentig, Nils ^a,d   Kaykhin, Pavel ^b   Stephan, Christoph ^b   Babacan, Errol ^b   Stürmer, Martin ^c   Staszewski, Schlomo ^b   Lötsch, Jörn ^a  

^a Institute of Clinical Pharmacology   (Germany)

^b Medical Clinics II   (Germany)

^c UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^d GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; ENFUVIRTIDE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; RITONAVIR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL;

DRUG MONITORING; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; OLIGOPEPTIDES; PYRIDINES; PYRIMIDINONES; RITONAVIR; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 44449100609     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01565-07     Document Type: Article

References (17)

1. Hoffito, M., M. Kurowski, G. Kruse, A. Hill, A. Benzie, M. Nelson, G. Moyle, B. Gazzard, and A. Pozniak. 2004. Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir boosted once-daily regimen. AIDS 18:1291-1297.
2. Boffito, M., D. Maitland, and A. Pozniak. 2006. Practical perspectives on the use of tipranavir in combination with other medications: lessons learned from pharmacokinetic studies. J. Clin. Pharmacol. 46:130-139.
3. Colombo, S., T. Buclin, and C. Franc. 2005. In vivo pharmacokinetic interaction study between boosted atazanavir and lopinavir for cellular, total and unbound plasma exposure in HIV-infected patients, abstr. 4.3/12. 10th European AIDS Conference EACS, Dublin, Ireland.
4. Johnson, V. A., F. Brun-Vezinet, B. Clotet, B. Conway, D. R. Kuritzkes, D. Pillay, J. M. Schapiro, A. Telenti, and D. D. Richman. 2005. Update of the drug resistance mutations in HIV-1: Fall 2005. Top. HIV Med. 13:125-131.
5. Kurowski, M., T. Sternfeld, A. Sawyer, A. Hill, and C. Mocklinghoff. 2003. Pharmacokinetic and tolerability profile of twice-daily saquinavir hard gelatin capsules and saquinavir soft gelatin capsules boosted with ritonavir in healthy volunteers. HIV Med. 4:94-100.
6. Lötsch, J., S. Harder, M. Stürmer, H.-W. Doerr, G. Geisslinger, S. Staszewski, and N. von Hentig. 2007. Association of saquinavir plasma concentrations with side effects but not with antiretroviral outcome in patients infected with protease inhibitor-susceptible human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 51:3264-3272.
7. Mouly, S., C. Matheny, M. Paine, G. Smith, J. Lamba, V. Lamba, S. Pusek, E. Schuetz, P. Stewart, and P. Watkins. 2005. Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5. Clin. Pharmacol. Ther. 78:605-618.
8. Pham, P. A., C. Flexner, T. Parsons, L. Vasist, E. Fuchs, K. Carson, S. Agarwala, and P. Barditch-Crovo. 2007. Beneficial pharmacokinetic interaction between atazanavir and lopinavir/ritonavir. J. Acquir. Immune Defic. Syndr. 45:201-205.
9. Ribera, E., C. Azuaje, R. Lopez, M. Diaz, M. Feijoo, L. Pou, M. Crespo, A. Curran, I. Ocana, and A. Pahissa. 2006. Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen. AIDS 20:1131-1139.
10. Sekar, V. J., E. Lefebvre, T. De Marez, S. Spinosa-Guzman, M. De Pauw, E. De Paepe, T. Vangeneugden, and R. M. Hoetelmans. 2007. Pharmacokinetics of darunavir (TMC114) and atazanavir during coadministration in HIV-negative, healthy volunteers. Drugs R&D 8:241-248.
11. Seminari, E., M. Guffanti, P. Villani, N. Gianotti, M. Cusato, G. Fusetti, A. Galli, A. Castagna, M. Regazzi, and A. Lazzarin. 2005. Steady-state pharmacokinetics of atazanavir given alone or in combination with saquinavir hard-gel capsules or amprenavir in HIV-1-infected patients. Eur. J. Clin. Pharmacol. 61:545-549.
12. Staszewski, S., E. Babacan, C. Stephan, A. Haberl, A. Carlebach, P. Gute, S. Klauke, Y. Hermschulte, M. Stuermer, and B. Dauer for the Frankfurt HIV Cohort. 2006. The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy. J. Antimicrob. Chemother. 58: 1024-1030.
13. Stephan, C., N. Hentig, I. Kourbeti, B. Dauer, M. Mosch, T. Lutz, S. Klauke, S. Harder, M. Kurowski, and S. Staszewski. 2004. Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavir. AIDS 18:503-508.
14. von Hentig, N. 2007. Lopinavir/ritonavir: appraisal of its use in HIV therapy. Drugs Today 43:221-247.
15. von Hentig, N., B. Dauer, A. Haberl, S. Klauke, T. Lutz, S. Staszewski, and S. Harder. 2007. Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults. Eur. J. Clin. Pharmacol. 63:935-940.
16. von Hentig, N., A. Haberl, A. Mueller, T. Lutz, S. Klauke, M. Kurowski, S. Harder, and S. Staszewski. 2005. Effect of atazanavir co-administration on the pharmacokinetics of either saquinavir, lopinavir or fosamprenavir when combined in ritonavir-boosted double protease inhibitor therapy regimens, abstr. PS 6/6. In 10th European AIDS Conference EACS, Dublin, Ireland.
17. von Hentig, N., A. Muller, C. Rottmann, T. Wolf, T. Lutz, S. Klauke, M. Kurowski, B. Oertel, B. Dauer, S. Harder, and S. Staszewski. 2007. Pharmacokinetics of saquinavir, atazanavir, and ritonavir in a twice-daily boosted double-protease inhibitor regimen. Antimicrob. Agents Chemother. 51:1431-1439.